in vivo News and Research

RSS

MGH, Duke University and Angion Biomedica partner to develop novel therapeutics for ischemic stroke

Angion Biomedica Corp. announced today the establishment of an alliance with Duke University and Massachusetts General Hospital to pursue advanced development and clinical studies of its lead therapeutics for treatment of ischemic stroke.

10 May 2011

Bruker announces new ultra-high field BioSpec 150/11 MRI system for preclinical research at ISMRM 2011

At ISMRM 2011, Bruker today announces a novel BioSpec 150/11 system, a new ultra-high field magnetic resonance imaging scanner for preclinical research that will open new frontiers in molecular and microscopic imaging.

10 May 2011

New York Academy of Sciences to host symposium on cutting-edge HIV/AIDS vaccine research

"Cracking the Safe: Advances in HIV/AIDS Prevention and Treatment" is a one-day symposium at the New York Academy of Sciences examining issues facing researchers working towards the development of an HIV/AIDS vaccine, including updates on current challenges and solutions.

10 May 2011

Researchers design new tool for identifying protein function from genetic code

Mayo Clinic researchers have designed a new tool for identifying protein function from genetic code. A team led by Stephen Ekker, Ph.D., succeeded in switching individual genes off and on in zebrafish, then observing embryonic and juvenile development.

10 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

Six1 transcription factor an essential regulator in development of embryonic lung epithelial stem cells

Scientists at The Saban Research Institute of Children's Hospital Los Angeles have provided the first evidence that Six1 transcription factor is an essential regulator in the development of embryonic lung epithelial stem cells.

6 May 2011

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, the world's most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

Clinical study: Celecoxib drug may treat breast cancer

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

5 May 2011

MiMedx introduces AmnioFix Nerve Wrap for use in surgical procedures

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix Nerve Wrap, the Company's latest biologic implant processed to offer surgical and healing options for nerve repair.

5 May 2011

Techne acquires Tocris Holdings

Techne Corporation announced today that it has acquired 100% ownership of Tocris Holdings Limited and subsidiaries, a leading supplier of reagents for non-clinical life science research.

3 May 2011

Caliper first quarter revenue increases 25% to $35.8 million

Caliper Life Sciences, Inc., today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010.

2 May 2011

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

2 May 2011

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Association's prestigious Apple Award.

30 Apr 2011

Gene therapy approach using CD59 shows promise against AMD: Study

A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration, according to a new in vivo study by researchers at Tufts University School of Medicine.

30 Apr 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.

27 Apr 2011

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra’s drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (“NT Life”), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

25 Apr 2011